EIGER BIOPHARMACEUTICALS INC CLDN
COM NEW · Common Stock · CUSIP 28249U204
2
institutional holders
-23 vs Q1 2024
146.4k
shares reported held*
$1.9mreported value*
0 new
0 added
1 reduced
23 sold out
net sold ≈ $6.2m (-521.1k shares)
* Summed across managers. Shares that two managers' reports both contain – a subsidiary's holdings that its parent's report includes too, or a sub-adviser's in its client's – are counted once. Holder counts are more reliable. Implied quarter-end price ≈ $12.65.
Trends to Q2 2024
Institutional holders
Managers reporting a position, each quarter
Numbers
| Quarter | Holders |
|---|---|
| Q1 2024 | 25 |
| Q2 2024 | 2 |
Biggest buyers
| None |
Biggest sellers
| AMERIPRISE FINANCIAL INC | Sold out | -250.2k |
| Simplify Asset Management Inc. | Sold out | -90.0k |
| Accretive Wealth Partners, LLC | Sold out | -63.1k |
| 683 Capital Management, LLC | Sold out | -29.7k |
| VANGUARD GROUP INC | Sold out | -28.2k |
| BlackRock Inc. | Sold out | -19.1k |
| GEODE CAPITAL MANAGEMENT, LLC | Sold out | -12.7k |
| RENAISSANCE TECHNOLOGIES LLC | Sold out | -11.1k |
| RBF Capital, LLC | Sold out | -11.0k |
| Tower Research Capital LLC (TRC) | Sold out | -1.9k |
Holders, Q2 2024
| Manager | Shares | Change |
|---|---|---|
| Propel Bio Management, LLC 1.20% of their portfolio | 146.4k $1.9m | Unchanged |
| OSAIC HOLDINGS, INC. 0.00% of their portfolio | 43 $543 | Reduced -288 |